Pioneering the Future of Oncology: Welcome to Targeted BioSciences’ Precision Medicine Revolution!
At T-Bio, we're transforming cancer treatment through revolutionary precision medicine technologies. Our innovative diagnostic, and singularly available platforms and targeted therapeutic approaches enable personalized treatment plans that dramatically improve patient outcomes while reducing side effects. By analyzing individual cancer profiles at the molecular level, we're making cancer treatment more effective, less invasive, and truly patient-specific.
Navigating the Complexities of Cancer Treatment - The Problem
Cancer treatment faces significant hurdles: ineffective standardized approaches, delayed diagnoses, harmful side effects, treatment resistance, and lack of personalization due to limited access to real-time genetic data.
Ineffective one-size-fits-all treatments
Traditional cancer treatments follow standardized approaches that ignore individual genetic makeup, leading to suboptimal outcomes when treatments aren't tailored to each patient's specific disease characteristics.
Delayed diagnoses
Cancer is often diagnosed at advanced stages, reducing treatment success rates. Factors include limited awareness, inadequate screening access, and difficulties detecting early-stage tumors.
Harmful side effects
While effective at killing cancer cells, chemotherapy and radiation damage healthy cells, causing debilitating side effects that impact quality of life and may limit patients' ability to tolerate treatment.
Treatment resistance
Cancer cells evolve and develop resistance to initially effective therapies, requiring doctors to constantly adapt treatment strategies to overcome these resistance mechanisms.
5
Lack of personalization
Without access to real-time genetic data to inform optimal treatment decisions, doctors often rely on less precise approaches that fail to address each patient's unique cancer characteristics.
Unlocking Precision: Our Personalized Solution to Effective Cancer Treatment
A step-by-step overview of our personalized cancer treatment platform.
Extra Cullular Vesicle (EV) Extraction
We capture EV’s from patient biofluids to isolate and analyze key biomarkers. Our proprietary extraction method ensures high purity and yield, enabling accurate downstream analysis.
Organelle Analysis
We then analyze organelle growth patterns to understand cellular behavior and identify potential drug targets. By examining mitochondrial function and other key organelle characteristics, we gain insights into the metabolic vulnerabilities of cancer cells.
Genetic Profiling
We can pinpoint specific mutations within cancer cells to inform treatment decisions. Our comprehensive genomic sequencing identifies actionable mutations, guiding the selection of targeted therapies.
Therapy Selection
Tailored treatment plans based on comprehensive patient data for personalized cancer therapy are established. Integrating genetic profiles, organelle analysis, and biomarker data allows us to customize treatment regimens for each patient, maximizing efficacy and minimizing side effects.
Our platform uses advanced techniques to extract vesicles, analyze organelles, perform genetic profiling, and tailor treatment plans for personalized cancer therapy. By leveraging cutting-edge technologies and comprehensive data analyses, we empower clinicians to make informed decisions and deliver precision medicine to cancer patients, improving outcomes and quality of life.
EV Testing Kits
Our EV Testing Kit delivers personalized cancer treatment results in hours with three critical outputs:
01 DIAGNOSTIC AND PREDICTIVE
Identifies cancer cells and their organ impacts.
02 MONITORING
Indicates tissues most responsive to targeted therapies.
03 ALERTS
Identifies all tissues affected by therapy and assesses treatment side effects.
These kits analyze biopsy fluid (EV’s) to assess cancer biomarkers. Unlike competitors using blood samples, our EV fluid testing uniquely evaluates the efficacy of oncologist-recommended targeted therapies.
Research Conducted using our EV Testing Platform
Our platform has enabled groundbreaking cancer research across multiple institutions. These studies demonstrate the effectiveness of our technology in identifying biomarkers and guiding treatment decisions.
Each study validates our platform's ability to accurately analyze cancer biomarkers and predict treatment responses, driving personalized medicine to target the cause.
The Acculift™ Laser-Capture Microscope
In addition to our EV Testing Platform, we patented a Laser-Capture Miscroscope that provides:
1
High-Resolution Analysis
Provides detailed genomic and proteomic assessment of cell structures and their reactions to anti-cancer therapies
2
Integrated Data Platform
Combines inputs from leading institutions like Stanford, Harvard, and Mayo Clinic into comprehensive treatment evaluations
3
Precision Targeting
Allows isolation of specific cells from tissue samples for accurate assessment of targeted therapies
Our patented system enables doctors to visualize cellular responses with unprecedented detail, leading to more effective therapies.
This builds on our innovative technologies to advance cancer treatment worldwide.
Global Traction: 30+ Acculift Microscope Systems Sold Worldwide
Our revolutionary Acculift™ systems are transforming cancer diagnostics across six continents. Leading institutions trust our technology to deliver unprecedented precision in cancer treatment planning.
Each installation represents a new center of excellence in personalized oncology care, directly impacting thousands of patient outcomes worldwide.
Research Conducted using our EV Testing Platform
Our platform has enabled groundbreaking cancer research across leading institutions. These studies demonstrate the platform's versatility and effectiveness in clinical settings.
Studies prove our technology delivers 85% faster diagnostics and 73% more precise treatment recommendations than traditional methods.
Research Conducted using our EV Testing Platform
Examples of Research Conducted using our EV Kit
1
George Mason University (GMU): TRIPLE NEGATIVE BREAST CANCER IMMUNOTHERAPY
Goal: Personalized Prediction of Cancer Immunotherapy Success, On-going Kit Tumor Tissue IF EV Validation
Status: Experimental Model Successful (N=75 Tumors), Publication Forth-coming Q4 2024
Northern VA Healthcare Corp. (INOVA): OVARIAN CANCER DRUG RESISTANCE
Goal: Understanding Ovarian Cancer Drug Resistance: Seeking Novel Therapeutic Strategies
Status: In progress: Patient Accrual (1/week), LCM-EV Biomarker Validation On-going, Q3-Q4 2024
3
Univ. Connecticut (UCONN): TESTING THERAPIES TO PREVENT COLON CANCER
Goal: New Strategies of Preventing Colon Cancer by modifying gut pre-malignant field.
Status: Feasibility Study Completed, Animal Trial Under Way, Data Expected by Q4 2024
UCONN-CORNELL: BLOCKING COLON CANCER IN HUMANS BY DIET MODIFICATIONS
Goal: Non-toxic dietary method of stopping colon cancer before it starts.
Status: Human tissue feasibility study completed, Finalizing Material Transfer and Trial Amendments Documentation
SENTARA Healthcare Corp.: PREDICTING CHOICE OF BREAST CANCER THERAPY TO ACHIEVE 100% REMISSION
Goal: Using novel biomarkers for predicting total therapeutic management.
Status: Blinded studies confirm biomarkers predicting complete response. Tissue protocol being implemented in hospitals. Reimbursement pathway established.
Eastern VA Med School: IMPROVED EARLY DIAGNOSIS OF PROSTATE CANCER
Goal: Treating only aggressive prostate cancers with new urine test, reducing overtreatment and suffering.
Status: Biomarkers Identified, Transfer of Protocol & Trial Amendments Paper Underway
Global Traction: 30+ Acculift Microscope Systems Sold Worldwide
Our cutting-edge microscopy technology has been adopted by leading research institutions and laboratories across the globe
North America
- Apic Bio, Inc. (2 systems)
- Avant Diagnostics, Inc (4 systems)
- Boston University
- George Mason University (2 systems)
- Kent State University
- Lyell Immuno Pharma, Inc.
- National Cancer Institute, U.S.A.
- National Institute of Health (NIH)
- University of Connecticut
- University of Maryland Medical School
- University of Massachusetts, Medical School
- Vanderbilt University
Europe
- ALAB Laboratory, Poland
- Excilone Pathology Lab, France
- Lunenfeld Tanenbaum Research Institute, Canada
- University Polytechnic, Italy
- University Hospital, Tubingen, Germany
- University of Turku, Finland
Asia-Pacific
- Hamamatsu University of Medicine, Japan
- National Cancer Center, Japan
Our technologies dramatically improve anti-cancer diagnostics & treatment results across all cancears.
Triple-Negative Breast Cancer
Negative for 3 main growth receptors, highly heterogeneous, aggressive, and metastatic.
Challenges:
Difficult to treat, poor response to immunotherapy.
Ovarian Cancer
Non-symptomatic until late stage, 28% survival rate after Stage III, 82% relapse rate after primary therapy, mechanism of resistance unknown, need for early diagnosis.
Colon Cancer
Cancer originates in certain polyps, early-stage detection prevents death, increase in young adult late-stage colon cancer, need for dietary and colonoscopy surveillance to prevent progression into lethal metastasis.
Prostate Cancer
High percentage of unnecessary overtreatment causing lifelong side effects, PSA test has low sensitivity & specificity, no predictive markers for aggressive cancers, need for new biomarkers.
Our EV Testing Products Lead the Market
Our comprehensive solution offers unmatched capabilities across testing methods, AI integration, and sample compatibility.
The chart clearly demonstrates our competitive edge - Targeted Biosciences offers all 8 critical capabilities, while our closest competitors provide only half that number. Our complete solution spans clinical trial usage, multi-omics technology integration, instrumentation, compatibility with multiple sample types (blood, urine, and tissue), diagnostic testing, and AI-powered predictive intelligence.
Only Targeted Biosciences offers a complete solution across all critical capability areas, positioning us as the market leader in personalized cancer diagnostics and treatment.
Projected Financial Growth
Our financial projections show strong revenue growth and profitability scaling from 2025-2029.
Our innovative cancer diagnostics platform drives a consistent 80% gross margin with breakthrough to profitability in 2027.
Excerpted Pro Forma Financial Highlights
Our five-year financial forecast demonstrates strong revenue growth and rapidly improving profitability metrics.
Our innovative cancer diagnostics platform achieves profitability in 2027 with consistent 80% gross margins throughout.
Road to Profitability
Cash-flow Positive
Breaking into positive territory by 2027 - just two years after launch.
Rapid Growth
Net income exceeds $2.3M by 2029, demonstrating exceptional scaling potential.
Investment Opportunity
$3M raise at $20M valuation with $400K already committed.
Investment Opportunity: $3M Raise
Strategic $3M raise at $20M valuation with $400K already committed, funding our next growth phase in cancer diagnostics.
TERMS
- $3M
- $20M Cap
- $400,000 already placed
- Rolling Close
ACHIEVEMENTS THUS FAR
- LCM commercially available worldwide
- TUV and CE marking completed
- Full Medicare Approval for test reimbursement
- $1 Million angel raise closed Dec 2024
Sales Growth Focus
Building high-performance sales team with industry veterans to accelerate hospital system adoption.
Why We Care
Precision Medicine
Our technology enables us to target treatments tailored to each patient's unique cancer profile, maximizing effectiveness while minimizing side effects and unnecessary interventions. Arresting cancer and creating quality of life and longevity are key goals.
Rapid Response Detection
We can closely monitor treatment effectiveness, often within days, allowing for quick adjustments to ease the journey and enhance quality of life for cancer patients.
Early Warning System
Molecular changes are detected early, even before symptoms appear, enabling proactive steps to keep cancer in check and prolong healthy living for the individual.
Accelerated Drug Development
Clinical trials are sped up, helping bring new and improved treatments to patients faster and more affordably, extending overall survival rates globally.
Who We Are
Targeted BioScience (TBS) is revolutionizing cancer care through precision medicine, delivering accelerated, individualized cancer diagnostics that significantly improve patient outcomes. We are diagnostic pioneers, cancer care innovators, and precision medicine leaders.
Diagnostic Pioneers
As leaders in tissue and (EV) diagnostics, Targeted BioScience’ pioneered patented profiling techniques that provide unparalleled insights into cancer at the molecular level. Our innovative approach enables earlier and more accurate detection, paving the way for personalized treatment strategies.
Cancer Care Innovators
We are redefining oncology through rapid, personalized detection and treatment solutions designed to minimize side effects and maximize patient comfort. By leveraging cutting-edge technology and a deep understanding of cancer biology, we are transforming the cancer care landscape.
Precision Medicine Leaders
We are setting new standards in targeted patient cancer care with unmatched diagnostic accuracy, ensuring that each patient receives the most effective treatment tailored to their unique cancer profile. Our commitment to precision medicine is driving improved outcomes and a better quality of life for cancer patients.
Our approach is rooted in scientific rigor, technological innovation, and a deep commitment to patient well-being and longevity, delivering what others can't: precision in cancer diagnostics.
The disruptive potential spans across breast, uterine, prostate, and colon cancers among others, eliminating the outdated one-size-fits-all approach to treatment. Our technology promises to transform the lives of countless individuals, offering new hope and improved outcomes in the fight against this devastating disease.
More Specifically We Are:
Alan Carpino, CEO
- 19+ years in Laser Capture Microgenomics markets
- Commercial Director at Fluidigm
- Senior Global Leader at ThermoFisher Scientific
- Research Investigator at Millennium Pharmaceuticals
Dr. Lance Liotta
- Co-Director of CAPMM at George Mason University
- Former Chief of Laboratory of Pathology at NCI
- Pioneered cancer metastatic process modeling
- Inventor of LCM and proteomics technologies
Noel Gonzalez, COO
- Former Nuclear Submarine Captain
- Secretary of Defense Fellow
- Stanford GSB and Harvard Hbx graduate
- Engineering and MBA background
Marian Sabety, Chairman
- 35 years in executive management
- Launched and exited global IP telephony company
- Co-founder of MyTelemedicine
- Chairman of Argus Enterprises, Inc.
THANK YOU
We appreciate your time and interest in Targeted BioScience.
Contact Our Leadership Team
Additional information on our patents and market opportunity follows.
Patent #63/417,485: Breakthrough EV Technology for Cancer Diagnostics
Using Extracellular Vesicles to test for Cancer - a novel approach that transforms cancer testing, individualized therapy, and treatment monitoring.
1
BREAKTHROUGH DISCOVERY
GMU researchers found that tissue interstitial fluid is a prolific source of extracellular vesicles (exosomes). These vesicles carry vital, real-time cellular data, guiding optimal drug selection and tracking therapy responsiveness.
PUBLISHED RESEARCH
First published in the International Society of Extra Vesicles, our discovery and method of harvesting tumor interstitial fluid EVs uses a non-destructive process essential for subsequent pathology and staging.
PATENT APPLICATION
US Provisional Application No.: 63/417,485 - "COLLECTION AND USE OF TISSUE RESIDENT INTERSTITIAL EXTRACELLULAR VESICLES"
PROTECTED INNOVATION
These EVs reveal a previously unexplored wealth of information not revealed by other diagnostic methods, positioning our technology at the forefront of cancer diagnostics and treatment.
Multiple Patents: Our Technological Advantage
AccuLift™ Analysis Platform
Our multi-dimensional tissue platform drives precision diagnostics through patented laser capture microdissection technology.
- U.S. Patent App. #15/388,919
- U.S. Prov. App. #62/798,131
Tissue Visualization Innovations
Our patented techniques enhance sample quality and digital imaging capabilities.
- U.S. Patent App. #63/112,321
- Liquid Cover Slip (Design Pat. App. #29/687,483)
End-to-End Process Protection
Our patent portfolio covers the complete workflow from preparation to analysis.
- U.S. Patent App. #63/111,955
- U.S. Prov. App. #62/678,731 (Organometallic labels)
Exploding Spatial Biology Market Opportunity
Our innovative platform targets three rapidly growing markets in spatial biology with a combined $1 trillion total addressable market by 2030.
Personalized diagnostics leads with explosive 16.5% CAGR, while AI-enabled microscopy analysis (10% CAGR) and multi-data digital pathology (7.1% CAGR) show strong sustained growth. Our technologies address all three market segments.
Let's partner to end needless suffering for cancer patients worldwide. Together, we can make a profound and lasting impact on countless lives, extending longevity while ensuring quality of life throughout the cancer journey.